Cathy Eng
MD, FACP, FASCO
Professor of Medicine; Co-Director, GI Oncology Program; David H. Johnson Chair in Surgical and Medical Oncology
👥Biography 个人简介
Cathy Eng, MD, FACP, FASCO is Professor of Medicine and Co-Director of the Gastrointestinal Oncology Program at Vanderbilt-Ingram Cancer Center, where she holds the David H. Johnson Chair in Surgical and Medical Oncology. Previously a longtime faculty member at MD Anderson Cancer Center, she is a globally recognized expert in the treatment of rectal cancer and anal cancer, with particular emphasis on optimizing neoadjuvant and total neoadjuvant therapy (TNT) strategies to improve organ preservation and long-term outcomes. Dr. Eng has been a driving force in the evolution of rectal cancer treatment toward total neoadjuvant approaches that deliver full systemic and radiation therapy before surgery, reducing distant recurrence and potentially enabling organ preservation in select patients with complete clinical response. She has led or contributed to multiple phase II/III trials evaluating induction chemotherapy followed by chemoradiation versus standard approaches in locally advanced rectal cancer. Her contributions have been pivotal in shaping NCCN and international guidelines for rectal and anal cancer management. As a prolific clinical trialist, educator, and mentor, Dr. Eng has authored more than 250 peer-reviewed publications and has served in leadership positions across ASCO, NCI cooperative groups, and multiple editorial boards. She is known for her patient advocacy and commitment to broadening access to cancer clinical trials for underrepresented populations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Total Neoadjuvant Therapy (TNT) for Rectal Cancer
Contributed clinical trial leadership and advocacy for total neoadjuvant therapy (TNT) approaches in locally advanced rectal cancer, demonstrating that administering systemic chemotherapy and chemoradiation before surgery improves distant recurrence rates and enables organ preservation in select patients achieving complete clinical response.
Neoadjuvant and Multimodal Rectal Cancer Treatment
Led multiple prospective trials evaluating induction chemotherapy regimens, optimal radiation sequencing, and multimodal strategies in locally advanced rectal cancer, informing current NCCN guideline recommendations for preoperative therapy.
Anal Cancer Clinical Trials and Treatment Standards
Conducted pivotal clinical trials and published widely cited analyses establishing standards for systemic therapy and chemoradiation in locally advanced and metastatic anal cancer, including evaluation of immune checkpoint inhibitors in this rare malignancy.
Access and Equity in GI Oncology Clinical Trials
Championed broadening access to GI oncology clinical trials for underrepresented minority populations, contributing to policy discussions on trial design and recruitment practices to ensure diverse representation in cancer research.
Representative Works 代表性著作
Total Neoadjuvant Therapy with FOLFOXIRI and Chemoradiation for Locally Advanced Rectal Cancer: Results of a Phase II Trial
Journal of Clinical Oncology (2019)
Phase II trial demonstrating the feasibility and efficacy of intensified total neoadjuvant therapy with FOLFOXIRI induction followed by chemoradiation in locally advanced rectal cancer, with high rates of pathologic complete response.
Nivolumab in Patients with Relapsed or Refractory Squamous Cell Anal Carcinoma (NCI9673)
Journal of Clinical Oncology (2017)
Phase II trial demonstrating meaningful clinical activity of nivolumab in previously treated metastatic squamous cell carcinoma of the anus, supporting immune checkpoint blockade as a treatment option in this rare cancer.
Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients with Metastatic Colorectal Cancer
Annals of Oncology (2014)
Clinical analysis evaluating the safety and efficacy of capecitabine plus bevacizumab as a less-intensive first-line regimen in older mCRC patients, informing treatment decisions for this often-underrepresented population in trials.
Organ Preservation in Rectal Cancer: The Promise of Total Neoadjuvant Therapy and Watch-and-Wait
Journal of the National Comprehensive Cancer Network (2020)
Comprehensive review of emerging evidence supporting organ-preserving strategies including watch-and-wait after complete clinical response to TNT in locally advanced rectal cancer, with practical guidance for patient selection and monitoring.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-05 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Cathy Eng 的研究动态
Follow Cathy Eng's research updates
留下邮箱，当我们发布与 Cathy Eng（Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment